AP NEWS

Global Ovarian Cancer Drugs Market Outlook, 2019-2023 with AstraZeneca, Clovis Oncology, F. Hoffmann-La Roche, Spectrum Pharmaceuticals, and Tesaro Dominating - ResearchAndMarkets.com

February 13, 2019

DUBLIN--(BUSINESS WIRE)--Feb 13, 2019--The “Global Ovarian Cancer Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The ovarian cancer drugs market will register a CAGR of over 22% by 2023.

Ovarian cancer is the second most common gynecologic cancer, and the incidence of the disease has been increasing. The incidence of ovarian cancer increases with age, mainly due to the cell DNA damage associated with age as a result of biological processes or due to the exposure to risk factors.

In terms of the incidence rate, ovarian cancer is the eighth-most commonly occurring malignancy in women and the eighteenth-most common cancer overall. Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period.

Increasing awareness of ovarian cancer

The increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.

High cost of treatment

The treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Key Players

AstraZeneca Clovis Oncology F. Hoffmann-La Roche Spectrum Pharmaceuticals Tesaro

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

Market definition Market sizing 2018 Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry

PART 07: MARKET SEGMENTATION BY TYPE

Comparison by type Epithelial ovarian cancer - Market size and forecast 2018-2023 Germ cell ovarian cancer - Market size and forecast 2018-2023 Stromal cell ovarian cancer - Market size and forecast 2018-2023 Small cell ovarian cancer - Market size and forecast 2018-2023 Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 RoW - Market size and forecast 2018-2023 Key leading countries Market opportunity

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors AstraZeneca Clovis Oncology F. Hoffmann-La Roche Spectrum Pharmaceuticals Tesaro

For more information about this report visit https://www.researchandmarkets.com/research/p2k932/global_ovarian?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190213005495/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Ovarian Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/13/2019 10:09 AM/DISC: 02/13/2019 10:09 AM

http://www.businesswire.com/news/home/20190213005495/en

AP RADIO
Update hourly